Latest news
Featured
Hikma delivers a solid H1 performance and re-affirms expectations for strong growth in the second half
Press Release, Financial Results
- Hikma Pharmaceuticals and Marius Pharmaceuticals announce licensing agreement for KYZATREX® (testosterone undecanoate) CIII capsules in Canada Press Release, Product 05 May 2026 Hikma Pharmaceuticals and Marius Pharmaceuticals announce licensing agreement for KYZATREX® (testosterone undecanoate) CIII capsules in Canada
- Hikma announces settlement agreement for VYNDAMAX® (tafamidis) Press Release, Corporate 28 April 2026 Hikma announces settlement agreement for VYNDAMAX® (tafamidis)
- Hikma reiterates full year 2026 guidance following encouraging start to the year Press Release, Financial Results 23 April 2026 Hikma reiterates full year 2026 guidance following encouraging start to the year
- Hikma launches authorised generic of Nucynta® ER (tapentadol) extended-release in the US Press Release, Product 11 March 2026 Hikma launches authorised generic of Nucynta® ER (tapentadol) extended-release in the US
Related content